Monday, 9 Nov 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US

ETR: MDG1

  • #
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
  • Rare / orphan disease drugs
  • Auto-immune
  • Vaccine
  • Cell-therapy
  • Multi-specific antibodies
  • CVD
  • AstraZeneca
  • Hengrui Pharmaceuticals
  • Diabetes
  • SHA: 600276
Bayer Signs Strategic Agreements with ACITS and GHIC at CIIE – Building an Open Innovation Ecosystem in Urological Oncology
CompanyDeals

Bayer Signs Strategic Agreements with ACITS and GHIC at CIIE – Building an Open Innovation Ecosystem in Urological Oncology

Bayer AG (ETR: BAYN) announced that, during the 9th China International Import Expo (CIIE), it signed strategic cooperation agreements with the Academy of Clinical Innovation and Translational Science (ACITS) and…

November 9, 2026
Hangzhou Diagens Forges Strategic Partnership with Yongjiang Laboratory – Deploying Medical Imaging Large Models Across Guangxi and ASEAN

Hangzhou Diagens Forges Strategic Partnership with Yongjiang Laboratory – Deploying Medical Imaging Large Models Across Guangxi and ASEAN

November 9, 2026
BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody

November 7, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
EpimAb and Medigene Team Up on TCR-TCE Therapy for Immune-Related Diseases
CompanyDeals

EpimAb and Medigene Team Up on TCR-TCE Therapy for Immune-Related Diseases

February 27, 2025
CompanyDrug

Medigene AG Secures Chinese Patent for TCR-T Therapy Targeting NY-ESO-1 and LAGE 1a

October 16, 2024
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up